123 results match your criteria: "Hematology and Clinical Immunology Unit[Affiliation]"
Hemasphere
December 2024
Dipartimento di Scienze di Laboratorio ed Ematologiche, Area Ematologia Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore Rome Italy.
J Antimicrob Chemother
November 2024
Dipartimento Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Roma, Italy.
Objectives: To evaluate clinical impact of ceftazidime/avibactam on treating infections due to MDR Gram-negative bacteria in patients with haematological malignancies (HMs).
Methods: We conducted a retrospective, observational study at 17 Italian haematological wards that included patients with HMs receiving ceftazidime/avibactam for the treatment of suspected or proven infections. The primary endpoint was all-cause mortality 30 days after infection onset.
Tissue Cell
December 2024
San Raffaele Telethon Institute for Gene Therapy, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
Colorectal cancer (CRC) affects approximately a million people annually with a mortality rate of 50 %, accounting for 8 % of cancer-related deaths globally. Molecular characterization by The Cancer Genome Atlas could be useful in these tumor subtypes to reveal "druggable" genes. Our study focuses on the significance of the AP3M2 gene (adaptor-related protein complex 3 subunit mu 2) as a potential oncogene by employing RNA interference to inactivate AP3M2.
View Article and Find Full Text PDFCurr Opin Allergy Clin Immunol
December 2024
Rare Diseases Referral Center, Internal Medicine 1, Department of Medicine (DIMED), AULSS2 Marca Trevigiana, Ca' Foncello Hospital, University of Padova, Padova, Italy.
Purpose Of Review: The pathogenesis of granulomatous disease in common variable immunodeficiency (CVID) is still largely unknown, which hampers effective treatment. This review describes the current knowledge on the pathogenesis of granuloma formation in CVID and the biological basis of the current treatment options.
Recent Findings: Histological analysis shows that T and B cells are abundantly present in the granulomas that are less well organized and are frequently associated with lymphoid hyperplasia.
Leuk Lymphoma
December 2024
Neurology Unit, Department of Neuroscience, University of Padova, Padova, Italy.
Crit Rev Oncol Hematol
September 2024
Department of Health Sciences (DISSAL) University of Genoa, Italy; Infectious Diseases Unit IRCCS Ospedale Policlinico San Martino Genoa, Italy.
Front Cell Dev Biol
January 2024
Department of Life Sciences, University of Siena, Siena, Italy.
Escape from immunosurveillance is a hallmark of chronic lymphocytic leukemia (CLL) cells. In the protective niche of lymphoid organs, leukemic cells suppress the ability of T lymphocytes to form the immune synapse (IS), thereby hampering T-cell mediated anti-tumoral activities. By binding its cognate receptor PD-1 at the surface of T lymphocytes, the inhibitory ligand PD-L1, which is overexpressed in CLL cells, mediates the T-cell suppressive activities of CLL cells.
View Article and Find Full Text PDFBlood Rev
May 2024
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
CLL is associated with an increased risk of infectious complications. Treatment with BTK or BCL-2 inhibitors does not seem to increase significantly the risk of opportunistic infections, but the role of combination therapies including BTK and/or BCL-2 inhibitors remains to be established. Various infectious complications can be successfully prevented with appropriate risk management strategies.
View Article and Find Full Text PDFVirchows Arch
March 2024
Hematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Hematol Oncol
January 2024
Hematology Unit, AO Cosenza, Cosenza, Italy.
Although chronic lymphocytic leukemia (CLL) predominantly affects the elderly, limited data exists about the outcomes of over 80-year-old patients, usually underrepresented in clinical trials. We conducted a multicenter study enrolling 79 consecutive CLL patients ≥80 years at the time of frontline therapy, all treated with ibrutinib. Nearly 48% of cases exhibited unmutated IGHV genes, 32% 17p deletion, and 39.
View Article and Find Full Text PDFEClinicalMedicine
November 2023
Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Virchows Arch
March 2024
Hematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria.
View Article and Find Full Text PDFFront Oncol
August 2023
Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Lübeck, Germany.
Br J Haematol
October 2023
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padua, Italy.
Signalling events downstream the B-cell receptor (BCR) are central for the survival and progression of chronic lymphocytic leukaemia (CLL) cells. Focal adhesion kinase (FAK), regulated through calpain, interacts with molecules of BCR signalling, cytoskeletal modelling and disease progression, such as Src/Lyn, cortactin and HS1. Hypothesizing that FAK might play a key role in CLL pathogenesis, we observed a down-modulation of FAK whole form, associated with FAK cleavage due to calpain activity upon BCR stimulation.
View Article and Find Full Text PDFFront Oncol
June 2023
Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy.
The approved combination of Tixagevimab/Cilgavimab has been shown to decrease the rate of symptomatic SARS-CoV-2 infection in patients at increased risk of inadequate response to vaccination. However, Tixagevimab/Cilgavimab was tested in a few studies that included patients with hematological malignancies, even if this population has shown an increased risk of unfavorable outcomes following infection (with high rates of hospitalization, intensive care unit admission, and mortality) and poor significant immunization following vaccines. We performed a real-life prospective cohort study to evaluate the rate of SARS-CoV-2 infection following pre-exposure prophylaxis with Tixagevimab/Cilgavimab in anti-spike seronegative patients compared to a cohort of seropositive patients who were observed or received a fourth vaccine dose.
View Article and Find Full Text PDFHematol Oncol
December 2023
Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Am J Hematol
September 2023
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
Cancers (Basel)
May 2023
National Center for Global Health, Istituto Superiore di Sanità, 00161 Rome, Italy.
High morbidity and mortality due to COVID-19 were described in the pre-vaccination era in patients with chronic lymphocytic leukemia (CLL). To evaluate COVID-19 morbidity after the SARS-CoV-2 vaccine, we carried out a prospective study in 200 CLL patients. The median age of patients was 70 years; 35% showed IgG levels ≤ 550 mg/dL, 61% unmutated IGHV, and 34% showed 53 disruption.
View Article and Find Full Text PDFFront Oncol
May 2023
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
Immune evasion is considered one of the modern hallmarks of cancer and is a key element in the pathogenesis of classical Hodgkin Lymphoma (cHL). This haematological cancer achieves effective avoidance of the host's immune system by overexpressing the PD-L1 and PD-L2 proteins on the surface of the neoplastic cells. Subversion of the PD-1/PD-L axis, however, is not the sole contributor to immune evasion in cHL, as the microenvironment nurtured by the Hodgkin/Reed-Sternberg cells is a major player in the creation of a biological niche that sustains their survival and hinders immune recognition.
View Article and Find Full Text PDFBiomolecules
March 2023
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padua, Italy.
The search for molecules to be targeted that are involved in apoptosis resistance/increased survival and pathogenesis of onco-hematological malignancies is ongoing since these diseases are still not completely understood. Over the years, a good candidate has been identified in the Heat Shock Protein of 70kDa (HSP70), a molecule defined as "the most cytoprotective protein ever been described". HSP70 is induced in response to a wide variety of physiological and environmental insults, allowing cells to survive lethal conditions.
View Article and Find Full Text PDFNeurol Neuroimmunol Neuroinflamm
July 2023
From the Department of Neurosciences (F.C., A.S., Chiara Briani), Neurology Unit, University of Padova; Hematology and Clinical Immunology Unit (A.V., A.C., L.T.), Department of Medicine, University of Padova; Department of Clinical and Experimental Medicine (E.S., G.S.), Neurological Clinic, University of Pisa; EMG Lab (M.C.), CEMES, Synlab Group, Padova; Immunology and Molecular Oncology (C.C., R.B.), Veneto Institute of Oncology IOV-IRCCS, Padova; and Department of Clinical and Experimental Medicine (Claudia Baratè), Section of Hematology, University of Pisa, Italy.
Background And Objectives: Neuropathy with antibodies to myelin-associated glycoprotein (MAG) is the most common paraproteinemic IgM neuropathy. Recently, the mutational profile of the and genes has been included in the diagnostic workup of IgM monoclonal gammopathies. The objective of our study was to assess the prevalence of and gene variants in patients with anti-MAG antibody neuropathy.
View Article and Find Full Text PDFJ Peripher Nerv Syst
June 2023
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy.
Aim: Neuropathy is a frequent complication of Waldenström's macroglobulinemia (WM), the most common being a demyelinating polyneuropathy with anti-myelin associated glycoprotein (MAG) antibodies, but also cryoglobulins, vasculitis, neurolymphomatosis, and amyloidosis. We describe a patient with IgM/kappa WM who presented with a severe, not length-dependent, peripheral neuropathy as clinical onset of IgM/kappa-related amyloidosis.
Methods: A 69-year-old woman came to our attention for weight loss, gait imbalance and sensory loss at upper limbs.
Br J Haematol
May 2023
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Br J Haematol
April 2023
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.